

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number
WO 02/086107 A2

(51) International Patent Classification: C12N 5/08, 5/02,
A61K 35/39, 35/48, C12Q 1/02, A61P 5/48

(21) International Application Number: PCT/EP02/04362

(22) International Filing Date: 19 April 2002 (19.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/284,531 19 April 2001 (19.04.2001) US

(71) Applicants (for all designated States except US):
DEVELOGEN AKTIENGESSELLSCHAFT FÜR
ENTWICKLUNGSBIOLOGISCHE FORSCHUNG
[DE/DE]; Rudolf-Wissell-Strasse 28, 37079 Göttingen
(DE). INSTITUT FÜR PFLANZENGENETIK UND
KULTURPFLANZENFORSCHUNG [DE/DE]; Cor-
rensstrasse 3, 06466 Gatersleben (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WOBUS, Anna,
M. [DE/DE]; Liebigweg 7, 06466 Gatersleben (DE).
ST-ONGE, Luc [CA/DE]; Rautenbreite 5, 37077 Göt-
tingen (DE). BLYSZCZUK, Przemyslaw [PL/DE];
Corrensstrasse 4a, 06466 Gatersleben (DE). HOFF-
MANN, Ursula [DE/DE]; Schedener Weg 28, 37127
Jühnde (DE).

(74) Agents: WEICKMANN, Franz, Albert et al.; Weick-
mann & Weickmann, Postfach 86 08 20, 81635 München
(DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: A METHOD FOR DIFFERENTIATING STEM CELLS INTO INSULIN-PRODUCING CELLS

(57) Abstract: The present invention relates a novel method for differentiating stem cells into insulin-producing cells by culturing such cells in specially defined media and optimally, activating one or more genes involved in beta-cell differentiation. The present invention further relates to applications in the medical (particularly diabetes) field that directly arise from the method of the invention. Additionally, the present invention relates to applications for identifying and characterising compounds with therapeutic medical effects or toxicological effects that directly arise from the method of the invention.

WO 02/086107 A2

A Method For Differentiating Stem Cells into Insulin-Producing Cells

Description

FIELD OF THE INVENTION

The present invention relates to methods for differentiating stem cells into insulin-producing cells by culturing such cells in specially defined mediums and optimally, activating one or more genes involved in beta-cell differentiation. The present invention provides means for treatment of pancreatic diseases, metabolic syndrome and metabolic disorders with impaired glucose levels, for instance, but not limited to, diabetes mellitus, hyperglycaemia and impaired glucose tolerance, by transplanting said insulin-producing cells into diabetic animals and humans. The methods can further be used to generate cells for the identification and characterisation of compounds which stimulate beta-cell differentiation, insulin secretion or glucose responsiveness. Differentiated insulin-producing cells can also be used to study the toxic and other effects of exogenous compounds on beta-cell function.

BACKGROUND OF THE INVENTION

Diabetes, hyperglycaemia and impaired glucose tolerance are endocrine disorders characterised by inadequate production or use of insulin, which affects the metabolism of carbohydrates, proteins, and lipids resulting in abnormal levels of glucose in the blood. Diabetes is a heterogeneous disease that can be classified into two major group: Type 1 diabetes (also known as Insulin-dependent diabetes, IDDM, type I, juvenile diabetes) and Type 2 diabetes (Noninsulin-dependent diabetes, NIDDM, type II, maturity-onset diabetes).

- 2 -

The functional unit of the endocrine pancreas is the islet of Langerhans which are scattered throughout the exocrine portion of the pancreas and are composed of four cell types: alpha-, beta-, delta-, and PP-cells. Beta-cells produce insulin, represent the majority of the endocrine cells and form the core of the islets while alpha-cells secrete glucagon and are located in the periphery. Delta-cells and PP-cells are less numerous and secrete somatostatin and a pancreatic polypeptide respectively. Insulin and glucagon are key regulators of blood glucose levels. Insulin lowers blood glucose levels by increasing its cellular uptake and conversion into glycogen. Glucagon elevates blood glucose levels by intervening in the breakdown of liver glycogen. Type 1 diabetes is characterised by an autoimmune destruction of insulin-producing beta-cells. Type 2 diabetes is characterised by insulin resistance and impaired glucose tolerance where insulin is not efficiently used or is produced in insufficient amounts by the beta-cells. Therefore, type 2 patients often require additional insulin to regulate blood glucose levels. Consequently, there is little therapeutic difference in the administration of insulin between type 1 and type 2 diabetic patients (see Fajans in Diabetes Mellitus fifth editions; Porte and Sherwin, ed; Appleton & Lange pub. 1997, 1423pp). Individuals afflicted with diabetes must inject themselves up to six times a day with insulin.

Despite insulin injections, diabetic patients develop complications and their susceptibility to strokes, blindness, amputations, kidney and cardiovascular diseases is greatly increased while their life expectancy is shortened (Nathan (1993) N. Engl. J. Med. 328:1676-1685; Group, T. D. C. a. C. T. R. (1993) N. Engl. J. Med. 329:977-986). Replacement of absent insulin-producing cells by transplantation of islets of Langerhans or insulin-producing cells is one promising therapeutic option (Luzi *et al.* (1996) J. Clin. Invest. 97:2611-2618; Bretzel *et al.* (1996) Ther. Umsch. 53:889-901) However, the availability of human donor tissue for transplantation is severely limited. An alternative option would be the use of animal tissues from pigs but serious technical problems such as long term

immunosuppression and the risk of transferring a porcine pathogen such as porcine endogenous retrovirus into the human population must be solved (Butler *et al.* (1998) Nature 391:320-324; Bach *et al.* (1998) Nature Med. 4:141-144; Shapiro *et al.* (2000) N. Engl. J. Med. 343:230-238). One solution to this problem would be to generate a human "surrogate cell" capable of assuming the functions of the missing or malfunctioning beta-cell. Therefore, there exists a need for producing an unlimited amount of surrogate insulin-producing cells for transplantation into diabetic patients. The present invention satisfies this need by providing an easy method for inducing the differentiation of stem cells into functional insulin-producing cells.

Stem cells are undifferentiated or immature cells that can give rise to various specialised cell types. Once differentiated or induced to differentiate, stem cells can be used to repair damaged and malfunctioning organs. Stem cells can be of embryonic or adult origin. Adult or somatic stem cells have been identified in numerous different tissues such as muscle, bone marrow, liver, and brain (Vescovi and Snyder (1999) Brain Pathol., 9:569-598; Seale and Rudnicki (2000) Dev. Biol., 218:115-124). In the pancreas, several indications suggest that stem cells are also present within the adult tissue (Gu and Sarvetnick (1993) Development, 118:33-46; Bouwens (1998) Microsc Res Tech, 43:332-336; Bonner-Weir (2000) J. Mol. Endocr., 24:297-302). However, this population is poorly defined and represents a very small percentage of cells in the pancreas.

Embryonic stem cells can be isolated from the inner cell mass of pre-implantation embryos (ES cells) or from the primordial germ cells found in the genital ridges of post-implanted embryos (EG cells). When grown in special culture conditions such as spinner culture or hanging drops, both ES and EG cells aggregate to form embryoid bodies (EB). EBs are composed of various cell types similar to those present during embryogenesis. When cultured in appropriate media, EB can be used to

generate *in vitro* differentiated phenotypes, such as extraembryonic endoderm, hematopoietic cells, neurons, cardiomyocytes, skeletal muscle cells, and vascular cells. No method has been described so far that allows EB to efficiently differentiate into insulin-producing cells.

5 Soria and colleagues describe a method for selecting insulin-secreting cell clones from ES cells using a cell-trapping system, wherein cells are transfected with a plasmid allowing the expression of neomycin resistance gene under the control of the regulatory region of the human insulin gene.
10 Cells from an insulin-secreting cell clone were implanted in the spleen of diabetic mice. The implanted cells can normalise blood glucose levels and restore body weight in the treated animals (Soria *et al.* (2000) *Diabetes* 49:157-162). A disadvantage of this selection method is, however, its low efficiency.

15 Lumelsky and colleagues (Lumelsky *et al.* (May 2001), *Science* 292: 1389-1394) have generated insulin-expressing cells from mouse ES cells. ES cells are expanded on a gelatine-coated tissue culture surface without feeder cells and in the presence of LIF. Then, embryoid bodies are
20 generated in suspension in ES cell medium in the absence of LIF. In a further stage nestin-positive cells are selected in a serum-free medium (ITSFn) on tissue culture surface. Resulting pancreatic endocrine progenitor cells are expanded and the differentiation and morphogenesis of insulin-secreting islet clusters is induced. However, the insulin-secreting islet
25 clusters did not restore normal blood glucose levels when transplanted into diabetic mice.

Assady *et al.* (August 2001), *Diabetes*, 50:1-7) describe a spontaneous *in vitro* differentiation of pluripotent human embryonic stem cells into cells
30 having the characteristics of insulin-producing cells. Secretion of insulin into the medium was observed in a differentiation-dependent manner and was associated with the appearance of other β -cell markers. However, the

- 5 -

efficiency of differentiation was low with only 1-3% of differentiated cells positive for insulin.

The present invention is aimed at inducing the differentiation of ES cells by activation of specific genes into insulin-producing cells and is therefore different from the methods of the prior art designed to select such cells.

In recent years, several genes have been shown to be essential for the generation of pancreatic endocrine cells during embryogenesis (Edlund (1998) *Diabetes*, 47:1817-1823; St-Onge *et al.* (1999) *Curr. Opin. Genet. Dev.*, 9:295-300). Pancreas development involves a series of inductive signals emanating from the surrounding mesodermic tissues and transcription factors expressed in the pancreatic epithelium. The homeobox containing transcription factor Pdx1 (also referred to Idx1, STF1, IPF1) is expressed in all cells of the pancreatic buds during development and will become restricted to the beta-cells in adult animals. Pdx1 mutant mice do not develop any exocrine nor endocrine tissue and do not have any pancreas (Jonsson *et al.* (1994) *Nature*, 371:606-609; Ahlgren *et al.* (1996) *Development*, 122:1409-1416; Offield *et al.* (1996) *Development*, 122:983-995). The basic helix-loop-helix transcription factor neurogenin3 (ngn3) is required for the specification of the early endocrine precursor in the pancreatic epithelium and is downregulated once endocrine differentiation begins (Apelqvist *et al.* (1999) *Nature*, 400:877-881; Jensen *et al.* (2000) *Diabetes*, 49:163-176; Gradwohl *et al.* (2000) *Proc. Natl. Acad. Sci. U.S.A.*, 97:1607-1611). Two members of the Pax gene family, Pax4 and Pax6, are essential for proper differentiation of endocrine cells in the pancreas (Sosa-Pineda *et al.* (1997) *Nature*, 386:399-402; St-Onge *et al.* (1997) *Nature*, 397:406-409; Sanders *et al.* (1997) *Genes Dev.*, 11:1662-1673). Both Pax genes are expressed early in development in a subset of endocrine precursor cells of the pancreatic epithelium, before differentiation of the mature hormone-producing cells. Mice lacking Pax4 fail to develop any beta-cells and are diabetic while the alpha-cell

- 6 -

population is absent in Pax6 mutant mice. Nkx2.2, Nkx6.1, Nkx6.2, Isl1, and NeuroD are also among essential transcription factors required for the proper differentiation and function of beta-cells.

5 Several animal models for beta-cell regeneration suggest that the mechanisms involved in beta-cell differentiation in adult organism are similar to the mechanisms involved in beta-cell differentiation during embryogenesis. Gu and Savernick have established a model system for studying pancreatic islet and beta-cell regeneration in transgenic mice
10 bearing the interferon-gamma (IFN-gamma) gene expressed in pancreatic islets. In this model, new islet cells (i.e. beta-, alpha-, delta- and PP-cells) are formed continuously from pancreatic duct cells (Gu and Savernick (1993) Development, 118:33-46). They show that duct cell proliferation and the duct-associated islet formation in IFN-gamma transgenic mice is
15 recapitulating islet formation during development and requires the expression of Pax4, Pax6 and Pdx1 genes. Although a link exists between the genes involved in islet regeneration in adult animals and beta-cell differentiation during embryogenesis, it has not been shown in the prior art that activation of such genes in stem cells can induce the differentiation
20 into insulin-producing cells.

SUMMARY OF THE INVENTION

25 The present invention relates a novel method for differentiating stem cells into insulin-producing cells by culturing such cells in specially defined media and optimally, activating one or more genes involved in beta-cell differentiation. The present invention further relates to applications in the medical and diabetes field that directly arise from the method of the invention. Additionally, the present invention relates to applications for
30 identifying and characterising compounds with therapeutic medical effects or toxicological effects that directly arise from the method of the invention.

- 7 -

DETAILED DESCRIPTION OF THE INVENTION

Before the present methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

A technical problem underlying the present invention is to provide a method for generating insulin-producing cells for transplantation in patients afflicted with pancreatic diseases, such as for example but not limited to, hyperglycaemia, impaired glucose tolerance, gestational diabetes, and diabetes mellitus. The solution to said technical problem is achieved by the embodiments characterised in the claims.

Thus, the present invention relates to methods for differentiating stem cells into insulin-producing cells comprising

- (a) Activating one or more pancreatic genes in a stem cell
- (b) Aggregating said cells to form embryoid bodies

- 8 -

- (c) Cultivating embryoid bodies in specific differentiation media enhancing beta-cell differentiation
- (d) Identification and selection of insulin-producing cells and of pancreatic cells.

5 In connection with the present invention, the term "stem cells" denotes an undifferentiated or immature embryonic, adult or somatic cells that can give rise to various specialised cell types. The term stem cells can include embryonic stem cells (ES) and primordial germ cells (EG) cells of human or
10 animal origin. Isolation and culture of such cells is well known to those skilled in the art (Thomson *et al.* (1998) *Science* **282**:1145-1147; Shambloot *et al.* (1998) *Proc. Natl. Acad. Sci. USA* **95**:13726-13731; US 6,090,622; US 5,914,268; WO 0027995; Notarianni *et al.* (1990) *J. Reprod. Fert.* **41**:51-56; Vassilieva *et al.* (2000) *Exp. Cell. Res.* **258**:361-
15 373). The term "stem cells" can include neural progenitor cells from embryonic, fetal or adult neural tissues. Isolation and culture of such cells is well known to those skilled in the art (Rao (Ed.), *Stem Cells and CNS Development*, Humana Press Inc., New Jersey (2001); Fedoroff and Richardson (Eds.), *Protocols for Neural Cell Culture*, Humana Press Inc.,
20 3rd edition, New Jersey, (2001)).

The term "insulin-producing cell" means a cell capable of expressing, producing, and secreting insulin.

25 The term "cultivation medium" means a suitable medium capable of supporting growth and differentiation of stem cells, preferably ES and EG cells. Examples of suitable culture media in practising the present invention are prepared with a base of Dulbecco's modified Eagle's medium (DMEM, Life Technologies) supplemented with 15% heat-inactivated foetal calf serum (FCS, Gibco), and additives, such as 2 mM L-glutamine (Gibco), 5 x
30 10⁻⁶M β -mercaptoethanol (Serva) and 1:100 non-essential amino acids (Gibco). Another example is a culture medium comprising Iscove's modified

- 9 -

Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, 2 mM L-glutamine (Gibco), 1:100 non-essential amino acids (Gibco) and 450 μ M α -monothioglycerol (Sigma). For routine cultures, ES cells are grown on a feeder layer of embryonic fibroblasts inactivated by treatment with 100 μ g/ml mitomycin C for 3 hours.

The term "differentiation medium" means a suitable medium for inducing the differentiation of stem cells into insulin-producing cells. Examples of suitable culture media in practising the present invention are prepared with a base of Iscove's modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% fetal calf serum (FCS), 2mM L-glutamine, 1:100 non-essential amino acids and 450 μ M α -monothioglycerol (Sigma). In addition, such medium can contain between 1 ng/ml and 100 μ g/ml, preferably 10 ng/ml Epithelial Growth Factor (EGF); between 1ng/ml and 100 μ g/ml, preferably 2 ng/ml basic Fibroblast Growth Factor (bFGF); between 1 nM and 1 mM, preferably 20 nM progesterone; between 10 ng/ml and 100 μ g/ml, preferably 100 ng/ml Growth hormone; between 1 nM and 100 μ M, preferably 5 nM follistatin (R&D); or between 1 and 100 nM, preferably 2nM activin (R&D). Another example of suitable culture media in practising the present invention is prepared with a base of Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (DMEM/F12, Life Technologies) supplemented with between 100 ng/ml and 100 μ g/ml, preferably 5 μ g/ml insulin; between 1 nM and 100 nM, preferably 30 nM sodium selenite; between 100 ng/ml and 500 μ g/ml, preferably 50 μ g/ml transferrin; between 100 ng/ml and 100 μ g/ml, preferably 5 μ g/ml fibronectin. Yet another example of suitable culture media in practising the present invention is prepared with a base of Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (DMEM/F12, Life Technologies) supplemented with between 100 ng/ml and 100 μ g/ml, preferably 25 μ g/ml insulin; between 1 nM and 100 nM, preferably 30 nM sodium selenite; between 100 ng/ml and 500 μ g/ml, preferably 50 μ g/ml transferrin; between 100 ng/ml and 100 μ g/ml, preferably 5 μ g/ml fibronectin;

- 10 -

between 500 ng/ml and 100 μ g/ml, preferably 1 μ g laminin; between 10 μ M and 500 μ M, preferably 100 μ M putrescine; between 1 nM and 1 μ M preferably 20 nM progesterone; between 100 μ M and 100 mM, preferably 10 mM nicotinamide.

5 In addition, extracellular matrix (ECM) proteins, such as laminin (between 0.5 and 100 μ g/ml, preferably 1 μ g/ml, SIGMA), or collagens, or complex mixtures of growth factors and ECM proteins of basal lamina (Matrigel R, Collaborative Research/Becton Dickinson, 1:3 dilution = stock solution,
10 final concentration in cultures = 1: 10) are included to enhance the number of pancreatic cells as well as their differentiation status.

The term "terminal differentiation medium" means a suitable medium for terminal differentiation of insulin-producing cells. Examples of suitable
15 culture media in practising the present invention are prepared with a base of Iscove's modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, 2mM L-glutamine, 1:100 non-essential amino acids and 450 μ M α -monothioglycerol (Sigma). In addition, such medium can contain between 1 nM and 100 μ M, preferably 2 nM Activin A; between 1nM and 100 μ M,
20 preferably 1 nM betacellulin; between 1 ng/ml and 100 μ g/ml, preferably 10 ng/ml Human Growth Factor (HGF); between 1nM and 100 μ M, preferably 10 nM Niacinamid and between 1 ng/ml and 100 μ g/ml, preferably 2 ng/ml Transforming Growth Factor 2beta (TGF 2beta).

25 The term "pancreatic gene" means a gene or its protein product that is involved and required for pancreas development, more preferably beta-cell differentiation. Examples of such genes are Pdx1 (GenBank accession number AH005712), Pax4 (GenBank accession numbers XM004974, NM006193), Pax6 (GenBank accession number M93650), ngn3 (GenBank
30 accession numbers XM005744, NM020999, AJ133776), Nkx6.1 (GenBank accession number AH007313), Nkx6.2, Nkx2.2 (GenBank accession number AF019415), HB9 (GenBank accession numbers

- 11 -

XMO49383, AF107457), BETA2/NeuroD (GenBank accession numbers NMO02500, XMO02573), Isl1 (GenBank accession number NM002202), HNF1-alpha, HNF1-beta (GenBank accession number X71346), and HNF3 (GenBank accession numbers AF176112, AF176111) of human or animal
5 origin. Preferred genes are Pdx1, Pax4, Pax6, and ngn3. Especially preferred genes are Pdx1, Pax4, and Pax6. Each gene can be used individually or in combination.

The term "activating one or more pancreatic gene" means delivering and
10 introducing said pancreatic genes or proteins into stem cells.

In a preferred embodiment, the cDNA of one or more pancreatic genes is placed under the control of a regulatory region allowing the initiation of transcription and introduced into a cell by transfection methods such as
15 electroporation, lipofection, calcium phosphate mediated, DEAE dextran, and the like. Such methods and system are well described in the art and do not require any undue experimentation; see, for example, Joyner, "Gene Targeting: A Practical Approach", Oxford University Press, New York, 1993; Mansouri "Gene Targeting by Homologous Recombination in
20 Embryonic Stem Cell", Cell Biology: A Laboratory Handbook, second ed., Academic Press, 1998. Gene expression of pancreatic gene can be assured by constitutive promoters such as the Cytomegalovirus promoter/enhancer region or inducible promoters such as the tetracycline inducible system. Expression vectors can also contain a selection agent such as the
25 neomycin, hygromycin or puromycin resistance genes. Making such gene expression vectors are well known in the art; see Sambrook *et al.*, "Molecular Cloning, A laboratory Manual" third ed., CSH Press, Cold Spring Harbor, 2000; Gossen and Bujard, (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551). DNA transfer can also be achieved using a viral
30 delivery system such as retrovirus, adenovirus, adeno-associated virus and lentivirus vectors.

In a further preferred embodiment, protein products of pancreatic genes can be delivered directly to stem cells. For example, protein delivery can be achieved by polycationic liposomes (Sells *et al.* (1995) *Biotechniques* 19:72-76), Tat-mediated protein transduction (Fawell *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 91:664-668) and by fusing a protein to the cell permeable motif derived from the PreS2-domain of the hepatitis-B virus (Oess and Hildt (2000) *Gene Ther.* 7:750-758). Preparation, production and purification of such proteins from bacteria, yeast or eukaryotic cells are well known by persons skilled in the art.

An additional embodiment of the present invention relates to a method for aggregating stem cells, preferably ES and EG cells, to form embryoid bodies. Embryoid bodies can be generated by a hanging drop method. For example, between 400-800 ES cells, preferably 600, are cultured in drops of 20 μ l of Iscove modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, L-glutamine, non-essential amino acids and α -monothioglycerol placed on the lids of petri dishes filled with phosphate-buffered saline (PBS). Embryoid bodies are cultured in hanging drops for 2 days at 37°C with 5% CO₂ and then transferred to bacteriological petri dishes (Greiner, Germany) and incubated a further 3 days in suspension culture. After 5 days, embryoid bodies are plated onto gelatin-coated 24-well plates, petri dishes or other suitable culture container and cultured for an additional 15 to 35 days at 37°C with 5% CO₂. Embryoid bodies can also be produced in spinner cultures. For example, adherent stem cells are enzymatically dissociated using 0,2% trypsin and 0,05% EDTA in PBS (Life Technologies) and seeded at a density of 10⁷ cell/ml in 250 ml siliconised spinner flasks (Life Technologies) containing 100 culture medium. After 24 hours, 150 ml culture medium is added to a final volume of 250. Spinner flasks are stirred at 20 rpm using a stirrer system (Integra Biosciences). Such methods are well known in the art and can be scaled up for industrial production without undue experimentation.

In a further embodiment of the invention, embryoid bodies are plated unto petri dishes containing differentiation medium and allowed to differentiate into insulin-producing cells for periods of 15 to 50 days, preferably 20 to 25 days (depending on the cell lines used; R1 wild type cells need longer
5 differentiation for generating insulin or glucagon-positive cells than Pdx-1⁺ or Pax4⁺ cells). In the method of the invention a high proportion of insulin-producing cells is obtained. After a differentiation time of 15 days, the proportion of insulin-producing cells is preferably at least 20%, more preferably at least 40% and most preferably at least 50%.

10 The proportion of insulin-producing cells may further be increased by a selection of nestin-positive cells. This selection preferably comprises the transfer of embryoid bodies, e.g. obtained by the hanging drop method, to a suspension culture and subsequent plating and/or replating on a suitable
15 medium, e.g. a poly-L-ornithine/laminin coated plate. The nestin selection procedure may lead to a further increase in the proportion of insulin-producing cells, e.g. a proportion of 70% or more.

In a further embodiment of the invention, differentiated insulin-producing
20 cells can be isolated and purified using a method for selecting insulin secreting cell clones from ES cells by transfecting cells with a plasmid allowing the expression of neomycin, hygromycin or puromycin resistance gene under the control of the regulatory region of the human insulin gene. Cells can also be sorted using Fluorescent Activated Cell Sorting (FACS)
25 after Hoechst 33342 dye staining (Goodell *et al.* (1996) J. Exp. Med. **183**:1797-1806). Further modifications of the above-mentioned embodiment of the invention can easily be devised by the person skilled in the art, without undue experimentation from this disclosure.

30 An additional embodiment of the present invention relates to a method for treating diabetes wherein between 3000 and 100 000 equivalent differentiated insulin-producing cells per kilogram body weight would be

introduced into a diabetic patient intraportally via a percutaneous transhepatic approach using local anaesthesia. Such surgical techniques are well known in the art and can be applied without any undue experimentation, see Pyzdrowski et al, "Preserved insulin secretion and insulin independence in recipients of islet autografts" New England J. Medicine 327:220-226, 1992; Hering *et al.*, "New protocol toward prevention of early human islet allograft failure" Transplantation Proc. 26:570-571, 1993; Shapiro *et al.*, "Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen", New England J. Medicine 343:230-238, 2000. Furthermore, encapsulation technology could also be used for the transplantation of differentiated insulin-producing cells as described by Lanza *et al.*, "Encapsulated cell technology", Nature Biotech 14:1107-1111, 1996.

Further, the invention relates to a cell composition comprising differentiated stem cells exhibiting insulin production, e.g. an insulin-producing cell line obtainable by the method as described above. The insulin-producing cells may exhibit a stable or a transient expression of at least one gene involved in β -cell differentiation, particularly a gene as described above. The cells are preferably human cells which are derived from human stem cells. For therapeutic applications the generation of autologous human cells from adult stem cells of a patient is especially preferred.

The insulin-producing cells of the invention exhibit characteristics which closely resemble naturally occurring β -cells. Particularly, the ratio of insulin-producing cells versus glucagon-producing cells is high. After 15 days of differentiation, this ratio is preferably at least 2:1 and more preferably at least 5:1. Further, the cells of the invention are capable of a quick response to glucose. After addition of 27.7 mM glucose, the insulin production is enhanced by a factor of at least 2, preferably by a factor of

at least 3 in the cells of the invention. Further, the cells of the invention are capable of normalizing blood glucose levels after transplantation into mice.

5 The cell composition of the invention is preferably a pharmaceutical composition comprising the cells together with pharmacologically acceptable carriers, diluents and/or adjuvants. The pharmaceutical composition is preferably used for the treatment of diabetes. The administration is preferably by transplantation as described above.

10 In a further embodiment, the present invention allows the generation of cells for the identification and/or characterisation of compounds which stimulate beta-cell differentiation, insulin secretion or glucose response. This method is particularly suitable for in vivo testing for diagnostic
15 applications and drug development or screening. The compound of interest is added to differentiated and undifferentiated insulin-producing cells which are grown in appropriate culture system, for example 96 and 384 well plates. Insulin levels in treated cells can be quantified by Enzyme Linked Immunoabsorbent Assay (ELISA) or Radio Immuno Assay (RIA). Using this
20 method, a large number of compounds can be screened and compounds that induce beta-cell differentiation and increase insulin secretion can be identified readily.

25 Preferred embodiments for high-throughput screening and medium throughput validation methods are described in Fig. 11. In a high-throughput screening method, the cells are transfected with a DNA construct, e.g. a viral or non-viral vector containing a reporter gene, e.g. the lacZ gene or the GFP gene, under regulatory control of a promoter of a gene involved in β -cell differentiation, e.g. a promoter of a gene as
30 described above, preferably a Pax4 promoter. The transfected cells are divided into aliquots and each aliquot is contacted with a test substance, e.g. candidate 1, candidate 2 and candidate 3. The activity of the reporter

- 16 -

gene corresponds to the capability of the test compound to induce β -cell differentiation.

In a further embodiment (which may be combined with the high-throughput screening as described above) a medium throughput validation is carried out. Therein, the test compound is added to stem cells being cultivated and the insulin production is determined. Following an initial high throughput assay, such as the cell based assay outlined above where e.g. a Pax4 promoter is used as marker for beta-cell regeneration, the activity of candidate molecules to induce beta-cell differentiation is tested in a validation assay comprising adding said compounds to the culture media of the embryoid bodies. Differentiation into insulin-producing cells is then evaluated, e.g. by comparison to wild type and/or Pax4 expressing ES cells to assess the effectiveness of a compound.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Expression vectors containing the Pdx1, Pax4, Pax6, and ngn3 gene.

The Pdx1, Pax4, Pax6, and ngn3 (SEQ ID No. 1, 2, 3, 4) cDNA were inserted into the expression vector pACCMV.pLpA previously described by Becker *et al.* (Becker *et al.* (1994) Meth. Cell Biol. 43:161-189). Briefly, a Kpn I-Bam HI fragment that included the Pdx1 cDNA (SEQ ID No.1) was introduced into the KpnI-BamHI sites of pACCMV.pLpA, placing the Pdx1 gene under the control of the Cytomegalovirus (CMVp) promoter. Likewise, a Bam HI-Hind III fragment that include the Pax4 cDNA (SEQ ID No. 2) was introduced into the Bam HI-Hind III sites of pACCMV.pLpA, placing the Pax4 gene under the control of the CMV promoter; a Bam HI-Hind III fragment that includes the Pax6 cDNA (SEQ ID No.3) was introduced into the Bam HI-Hind III sites of pACCMV.pLpA, placing the Pax6 gene under the control of the CMV promoter; and a Bam HI-Xba I that includes the ngn3 cDNA

- 17 -

(SEQ ID No. 4) was introduced into the Bam HI-Xba I sites of pACCMV.pLpA, placing the ngn3 gene under the control of the CMV promoter. Abbreviations: B, Bam HI; H, Hind III; K, Kpn I; X, Xba I; Ad 5, adenovirus type 5.

Figure 2. Differentiation of ES cells into insulin-producing cells

Wild type and Pdx1 expressing embryonic stem (ES) cells were cultivated as embryoid bodies (EB; EBs) by the hanging drops method. Differentiation and terminal differentiation media are applied upon plating of EBs.

Figure 3. Amount of hormone-producing cells in Pdx1+ differentiated ES cells

Immunofluorescence observation of insulin, glucagon, pancreatic polypeptide (PP) and somatostatin-positive cells following plating of Pdx1 + embryoid bodies cultured in normal culture medium and differentiation medium. Results illustrated over time in arbitrary units representing the average number of hormone-producing cells in define areas of the culture dishes. The number of hormone-producing cells (i.e. insulin, glucagon, PP, and somatostatin) is higher when embryoid bodies are cultured in differentiation and terminal differentiation media.

Figure 4. Expression of pancreas specific genes after differentiation of wild type, Pdx1⁺, and Pax4⁺ ES cells into insulin-producing cells.

mRNA levels of pancreas specific genes following formation of embryoid bodies by the hanging drop method and plating in differentiation medium. Insulin and Glut2 levels are higher in Pdx1⁺ and Pax4⁺ ES cells than in wild type ES cells indicating that differentiation is more efficient when a pancreatic developmental control gene is activated.

Figure 5. Differentiation of mouse ES cells into insulin-producing cells.

The proportion of insulin-producing cells was determined in wild type cells (R1), and Pdx1 and Pax4 expressing cells, 5, 6, 10, and 15 days after plating.

Figure 6. Insulin-producing cells versus glucagon-producing cells.

The expression of insulin and glucagon in wild type ES cells, Pdx1 expressing cells and Pax4 expressing cells was determined 5, 10 or 15 days after plating.

Figure 7. Glucose response of Pax4 ES cell derived insulin cells.

The insulin secretion of wild type (R1) and Pax4 ES derived insulin-producing cells was determined in the absence of glucose and 15 minutes after stimulation with 27.7 mM glucose.

Figure 8. Regulation of blood glucose level in diabetic mice.

The blood glucose level of diabetic control mice (STZ control) and diabetic mice having received a transplant of insulin-producing cells derived from Pax4 ES cells was determined.

Figure 9. Drug screening strategies.

A high-throughput screening and a medium throughput validation method for three test compounds are shown. An initial high throughput screen is performed in a cell assay using Pax promoters as reporter for beta-cell differentiation. Positive candidates are then validated in a medium throughput assay involving embryoid bodies. Compounds are tested at

- 19 -

different stages of culture for their potential to induce the formation of insulin-producing cells.

Figure 10. Differentiation methods of ES cells into insulin-producing cells using culture conditions favouring the formation of nestin-positive cells.

Figure 11. Differentiation of nestin-positive mouse ES cells into insulin-producing cells.

EXAMPLES

A better understanding of the present invention and of its many advantages will be had from the following examples, given by way of illustration.

Example 1: Generation of ES cells expressing the Pdx1 or Pax6 gene.

The mouse R1 ES cells (Nagy *et al.* (1993) Proc. Natl. Acad. Sci. U S A. 90:8424-8) were electroporated with the Pax6 or the Pdx1 gene under the control of the CMV promoter (see figure 1) and the neomycin resistance gene under the control of the phosphoglycerate kinase I promoter (pGK-1). ES cells are cultured in Dulbecco's modified Eagle's medium (DMEM, Life Technologies) containing 4.5 g/l glucose, 10^{-4} M beta-Mercaptoethanol, 2nM glutamine, 1% non essential amino acids, 1 nM Na-pyruvate, 15% FCS and 500 U/ml leukaemia inhibitory factor (LIF). Briefly, approximately 10^7 ES cells resuspended in 0.8 ml phosphate buffered saline (PBS) containing 25 μ g/ml of linearized expression vector and electroporated with one pulse of 500 μ F and 250 volts at room temperature using a Gene Pulser electroporation apparatus (BioRad). Five minutes after electroporation, ES cells are plated on 8.5 cm petri dishes containing fibroblastic feeder cells previously inactivated by treatment with 100 μ g/ml mitomycin C for 3 hours. One day after electroporation, culture medium is

- 20 -

changed to medium containing 450 μ g/ml G418. Resistant clones are separately isolated and cultured 14 days after applying the selection medium. Cells are always cultured at 37°C, 5% CO₂.

5 **Example 2: Differentiation of ES cells into insulin-producing cells.**

The ES cell line R1 (wild type, wt) and ES cells constitutively expressing Pdx1 (Pdx1+) were cultivated as embryoid bodies (EB; EBs) by the hanging drops method (Figure 2). Briefly, approximately 600 cells were
10 placed in drops of 20 μ l medium composed of Iscove modified Dulbecco's medium (IMDM, Gibco) supplemented with 20% FCS, L-glutamine, non-essential amino acids and alpha-monothioglycerol (Sigma, Steinheim, Germany; final concentration 450 μ M). Drops were placed on the lids of petri dishes filled with phosphate-buffered saline (PBS). The EBs were
15 allowed to form in hanging drops cultures for 2 days and then transferred for three days to suspension cultures in bacteriological petri dishes (Greiner, Germany). At day 5, EBs were plated separately onto gelatin-coated 24-well plates containing a differentiation medium prepared with a base of Iscove modified Dulbecco's medium (IMDM, Gibco) supplemented
20 with 20% FCS, 2mM L-glutamine, 1:100 non-essential amino acids, 450 μ M α -monothioglycerol (Sigma), 10 ng/ml Epithelial Growth Factor (EGF, R&D Research), 2 ng/ml basic Fibroblast Growth Factor (bFGF, R&D Research), 20 nM progesterone (R&D Research), 100 ng/ml Human Growth Hormone (HGH, R&D Systems) and 5 nM follistatin (R&D Systems) and/or
25 2nM human activin A (R&D Systems). Cells were cultured for 15 to 40 days in the differentiation medium. To enhance differentiation capacity, a terminal differentiation medium can be applied at stages between 5 and 20 days after EB plating.

Example 3. Hormonal expression in differentiated ES cells.

Expression of insulin, glucagon, somatostatin and pancreatic polypeptide (PP) was verified by immunofluorescence in differentiated wt and Pdx1 + ES cells. Immunofluorescence was performed according to standard protocols (see Wobus *et al.*: In Vitro Differentiation of Embryonic Stem Cells and Analysis of Cellular Phenotypes, In: Tymms, M.J. and Kola, I. (Eds.) Gene Knockout Protocols, vol. 158, Methods in Molecular Biology, Humana Press, Totowa, New Jersey, 2001). Briefly, differentiated wt or Pdx1 + ES cells are grown on cover slips and rinsed twice with PBS and fixed with methanol: acetone 7:3 at -20°C for 10 min. The following antibodies were used: Mouse anti-insulin (Sigma-Aldrich Co.), rabbit anti-glucagon (Dako Corporation), rabbit anti-somatostatin (Dako Corporation), rabbit anti-PP (Dako Corporation) were used as primary antibody while Fluorescein (DTAF)-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories) and Cy³™-conjugated goat anti rabbit IgG (Jackson ImmunoResearch Laboratories) were used as second antibody. In this study double immunostaining was performed, and the following pairs of antibodies were used: anti-insulin and anti-glucagon; anti-insulin and anti-somatostatin; anti-insulin and anti-PP. Cells were analyzed with a fluorescence microscope Optiphot-2 (Nikon) and a confocal laser scanning microscope (CLSM) LSM-410 (Carl Zeiss). Differentiated wt ES cells co-express insulin, glucagon, PP, and somatostatin indicating that the cells have not undergone maturation into single hormone-producing cells. However, differentiated Pdx1 + cells separately express either insulin or glucagon but, rarely both hormones at the same cells demonstrating that such cells achieve maturation into single hormone-producing cells. The number of hormone-producing cell is higher when Pdx1 + ES cells are cultured in a differentiation medium (see Fig.3) illustrating that differentiation into insulin-producing cells is more efficient when a pancreatic developmental control gene is expressed in a stem cell (e.g. ES) and when such cells are cultured in a differentiation medium.

Example 4: Expression of pancreas specific genes after differentiation of ES cells into insulin-producing cells.

Expression levels of pancreas specific genes was measured by semi-quantitative RT-PCR analysis. Differentiated wild type, Pdx-1⁺ and Pax4⁺ cells have been collected after embryoid body formation (5d) and 2, 7, 10, 15, 21 and 24 days after plating (5 + 2d, + 7d, + 10d, + 15d, + 21d, + 24d) were suspended in lysis buffer (4 M guanidinium thiocyanate, 25 mM sodium citrate, pH 7; 0.5% sarcosyl, 0.1 M beta-mercaptoethanol). Total RNA was isolated by the single step extraction method described by Chomczynski and Sacchi (Chomczynski and Sacchi (1987) Anal. Biochem. 162: 156-159). mRNA was reverse transcribed using PolyT tail primer Oligo d(T)₁₈ (PerkinElmer) and the resulting cDNA was amplified using oligonucleotide primers complementary and identical to transcripts of the following genes: GLUT2 (SEQ ID No 9 and 10; annealing temperature 60°C for 40 cycles, expected fragment size 556 bp), insulin (SEQ ID No 11 and 12; annealing temperature: 60°C for 40 cycles, expected fragment size 340 bp), ngn-3 (SEQ ID No 13 and 14; annealing temperature: 60°C for 40 cycles, expected fragment size 514 bp), Pdx-1 (SEQ ID No 15 and 16; annealing temperature: 60°C for 45 cycles, expected fragment size 230 bp) and Isl1 (SEQ ID No 17 and 18; annealing temperature: 60°C for 40 cycles, expected fragment size 514 bp). The house keeping gene beta-tubulin (SEQ ID No 19 and 20, annealing temperature: 60°C for 28 cycles, expected fragment size 317 bp) was used as internal standard. Reverse transcription (RT) was performed with MuLV reverse transcriptase (Perkin Elmer). Multiplex PCRs were carried out using AmpliTaq DNA polymerase (Perkin Elmer) as described in Wobus et al., 1997. Briefly, RT reactions (20 µl) were performed with MuLV reverse transcriptase. Separate PCRs using primers of the analysed genes or primers of the house keeping gene beta-tubulin were carried out with 3 µl of the RT products.

mRNA levels of genes encoding Pax4 and insulin were analysed using the Dynalbeads mRNA DIRECT micro kit (Dynal) according to the manufacturer's instructions.

- 5 One third of each PCR reaction was separated by electrophoresis on 2% agarose gels containing 0.35 μ g/ml of ethidium bromide. Gels were illuminated with UV light and the ethidium bromide fluorescence signals of gels were stored by the E.A.S.Y. system (Herolab) and analyzed by the TINA2.08e software (Raytest Isotopenmeßgeräte GmbH). The intensity of
- 10 the ethidium bromide fluorescence signals was determined from the area under the curve for each peak and the data of target genes were plotted as percentage changes in relation to the expression of the housekeeping gene beta-tubulin.
- 15 Results show that markers for beta-cell differentiation function were expressed at higher levels in Pdx1⁺ and Pax4⁺ differentiated ES cells than in differentiated wild type ES cells demonstrating that activation of a pancreatic developmental control gene renders differentiation more efficient than for wild type ES cells (Figure 4). Expression of GLUT2 in differentiated
- 20 stem cells indicates that hormone-producing cells are capable of responding to glucose. In addition, genes involved in early endodermal/pancreatic precursor cell specification such as ngn3 and Isl1 are downregulated in Pdx-1⁺ and Pax4⁺ ES cells, consistent with *in vivo* data indicating that such cells have matured into single hormone-producing
- 25 cells.

Example 5: Hormonal expression of differentiated ES cells expressing Pdx1 and Pax4

- 30 In order to study the potential of pancreatic developmental control to induce beta-cell differentiation *in vitro*, we have generated stable mouse embryonic stem (ES) cells expressing the Pax4 or Pdx1 gene under the

control of the cytomegalovirus (CMV) early promoter/enhancer region (see Figure 1a,b). The CMV-Pax4 and CMV-Pdx1 transgenes were introduced into ES cells by electroporation, a method that is well known in the art, for example see Joyner, "Gene Targeting: A Practical Approach", Oxford University Press, New York, 1993; Mansouri "Gene Targeting by Homologous Recombination in Embryonic Stem Cell", Cell Biology: A Laboratory Handbook, second ed., Academic Press, 1998. Pax4, Pdx1 and wild type ES cells were then cultured in hanging drops or spinner cultures to allow the formation of embryoid bodies. Embryoid bodies were subsequently plated and cultured in a differentiation medium containing various growth factors. Under such conditions, insulin-producing cells can be detected in Pdx1 and Pax4 expressing cells six days after plating (Figure 5). By comparison, wild type ES cells did not contain any insulin-producing cell at the same stage. Ten days after plating, 12% of Pdx1 and Pax4 expressing cells were positive for insulin while the first insulin-producing cells are observed in wild type ES cells. At day 15 of plating, up to 60% of the Pax4 ES cells are positive for insulin compared to 22% for Pdx1 ES cells and 6% for wild type ES cells. These data demonstrate that Pax4, and to some extent Pdx1, can significantly promote, and enhance ES cells differentiation into insulin-producing cells compared to wild type ES cells.

The expression of Pax4 also affects the differentiation status of the insulin-producing cell. During embryogenesis, the first hormone-producing cells to arise in the developing pancreas co-express both insulin and glucagon. These cells subsequently differentiate and mature into single hormone-producing cells. In a similar fashion, all insulin-producing cells obtained from wild type ES cells also co-express glucagon suggesting that differentiation of the cells is arrested at a premature stage (Figure 6). Such cells most likely have little therapeutic value since insulin and glucagon have opposing effect on blood glucose levels in an organism. However in Pax4 ES cells, single insulin-producing cells are generated in substantial amounts (Figure 6). Insulin-glucagon co-expressing cells are detected in

small numbers and most likely represent an ongoing differentiation process within the cultures. This observation demonstrate that Pax4 induces, and enhances the differentiation of insulin-producing cells which are more mature than the cells observed in wild type ES cells.

Example 6: Functional characterisation of the differentiated insulin-producing cells.

One important property of beta-cells is glucose responsive insulin secretion. To test whether the Pax4 derived insulin-producing cells possessed this glucose responsive property, in vitro glucose responsive assay was performed on the differentiated cells. Briefly, between 10 and 14 embryoid bodies were cultured in 3 cm petri dishes containing the above mentioned differentiation medium. On the day of the assay, the differentiation medium was removed and the cells were washed 3 times with Krebs Ringer Bicarbonate Hepes Buffer (KRBH; 118 mM NaCl, 4.7 KCl, 2.5 mM CaCl_2 , 1.2 mM KH_2PO_4 , 1.2 mM MgSO_4 , 24.6 mM NaHCO_3 , 10 mM Hepes, 2 mg/ml BSA). Cells were then incubated in 750 μl KRBH for 45 minutes at 37°C. The KRBH was then kept for measurement of basal insulin secretion and 750 μl KRBH containing 27.7 mM glucose was added to the cells. After 15 minutes incubation at 37°C, the KRBH was removed from the cells for measurement of glucose induce insulin secretion. Insulin levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) for mouse insulin (Mercodia) and performed according to the manufacturer's recommendations. An alternative medium for proper insulin release is medium based on DMEM with glucose concentration of 1 g/l (Gibco) supplemented with non-essential amino acids (Gibco, stock solution 1:100) and additional factors mentioned above. Such medium can be applied 1 to 6 days before use of the cells.

A basal insulin secretion is observed when both wild type and Pax4 ES derived insulin-producing cells are cultured in the absence of glucose

(Figure 7). However, only the Pax4 ES derived insulin-producing cells respond to glucose stimulation. In the presence of glucose, a five fold increase in insulin secretion is seen in Pax4 ES derived insulin-producing cells. Wild type ES derived insulin-producing cells do not respond to glucose.

Example 7: Transplantation of Pax4 ES derived insulin-producing cells in STZ diabetic mice.

The therapeutic potential of Pax4 ES derived insulin-producing cells to improve and cure diabetes was investigated by transplanting the cells into streptozotocin induced diabetic mice. Streptozotocin is an antibiotic which is cytotoxic to beta-cells when administered at certain dosage (see Rodrigues et al.: Streptozotocin-induced diabetes, in McNeill (ed) Experimental Models of Diabetes, CRC Press LLC, 1999). Its effect is rapid, rendering an animal severely diabetic within 48 hours.

Non-fasted Male BalbC mice were treated with 170 mg/Kg body weight STZ. Under such conditions, 17 control mice developed hyperglycaemia 6 days after STZ treatment. Mice are considered diabetic if they have a blood glucose level above 10 mMol/l for more than 3 consecutive days. One mouse did not respond to the STZ treatment. Elevated blood glucose levels varied significantly between animals and between days. This is indicative of diabetes since the animals cannot regulate their blood glucose. Cells were transplanted under the kidney capsule and into the spleen of animals. Briefly, mice were anaesthetised by intraperitoneal injection of 15 μ l/g body weight avertin (2,5% tribromoethyl alcohol:tertiary amyl alcohol). The kidney and the spleen was exposed through a lumbar incision, and cells were transferred into each tissue using a blunt 30G needle.

Transplantation of cells under the kidney capsule and into the spleen were performed 24-48 hours after STZ treatment. 8 animals were transplanted

with between 1×10^6 and 5×10^6 Pax4 ES derived insulin-producing cells. 4 out of 8 transplanted animals died due to the surgical procedure. Of the 4 animals that did survive, none developed diabetes when compared with STZ-treated control animals (Figure 8). The presence of the insulin-producing cells was confirmed by immunohistological analysis of the transplanted tissue. These results demonstrate that the transplanted cells can normalise blood glucose in diabetic animals.

Example 8: Differentiation of ES cells into insulin-producing cells using culture conditions favouring the formation of nestin-positive cells.

For differentiation of nestin-positive cells, mouse ES cells were cultivated for 2 days in hanging drops (100, 200, or 400 cells/drop) to form embryoid bodies (EBs; Figure 10). EBs were then transferred to bacteriological petri dishes (Greiner, Germany) and cultivated for additional 2 days in Iscove's modification of DMEM (IMDM; Gibco) containing 20% FCS and supplements as described (Rohwedel et al., 1998), Dev. Biol. 201(2):167-184, with the exception that beta-mercaptoethanol was replaced by 450 mM alpha-monothioglycerol (Sigma, Steinheim, Germany). Between 20 and 30 EBs were plated onto tissue culture dishes (diameter 6 cm) at day 4, and cultivated in IMDM supplemented with 20% FCS for 24 hours. The selection of nestin-positive cells was carried out according to the method described by Okabe and colleagues (Okabe et al., 1996, Mech. Dev. 59:89-102) with the following modifications: After attachment of EBs (day 4 + 1), the medium was exchanged for a B1 medium prepared with a base of Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (DMEM/F12, Life Technologies) supplemented with 5 mg/ml insulin, 30 µg/ml sodium selenite (both from Sigma), 50 mg/ml transferrin, and 5 mg/ml fibronectin (both from Gibco). The B1 culture medium was replenished every 48 hours. Nestin-positive cells were selected after cultivation for 7 days (= 4 + 7d). At day 4 + 8, EBs were dissociated with 0.1% trypsin (Gibco)/0.08% EDTA (Sigma) in phosphate buffered saline (PBS) (1:1) for

- 28 -

1 min, collected by centrifugation, and replated onto poly-L-ornithine/laminin-coated tissue culture dishes containing a B2 medium prepared with a base DMEM/F12 supplemented with 10% FCS; 20 nM progesterone; 100 mM putrescine; 1 mg/ml laminin (all from Sigma); 25
5 mg/ml insulin; 50 mg/ml transferrin; 30 nM sodium selenite; B27 supplement; and 10 mM nicotinamide. This medium was replaced after 24 hours with B2 medium lacking FCS. At day 30 of plating; >75% of the Pax4 ES cells are positive for insulin compared to 20% for wild type ES cells (Figure 11).

10 All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the
15 invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related
20 fields are intended to be within the scope of the following claims.

Claims

1. A method for differentiating stem cells into insulin-producing cells
5 comprising:
culturing stem cells in a suitable medium and activating at least one
gene involved in beta-cell differentiation.
2. The method of claim 1 further comprising:
10 aggregating said cultivated stem cells to form embryoid bodies,
cultivating said embryoid bodies in a differentiation medium
enhancing β -cell differentiation, identifying, and optionally selecting
insulin-producing cells.
3. The method of claim 1 or 2, wherein said stem cells are selected
15 from embryonic stem cells, adult stem cells, somatic stem cells and
primordial germ cells.
4. The method of any one of claims 1-3, wherein said stem cells are of
20 human origin.
5. The method of any one of claims 1-4, wherein the genes involved in
 β -cell differentiation are selected from the group consisting of Pdx1,
Pax4, Pax6, ngn3, Nkx6.1, Nkx6.2, Nkx2.2, HB9, BETA2, NeuroD,
25 Isl1, HNF1-alpha, HNF1-beta, HNF3, and combinations thereof.
6. The method of claim 5, wherein the genes are selected from Pdx1,
Pax4, Pax6, ngn3, and combinations thereof.
- 30 7. The method of claim 5 or 6, wherein the genes are of human origin.

- 30 -

8. The method of any one of claims 1-7, wherein the gene activation comprises a delivery of a pancreatic gene into stem cells.
9. The method of claim 8, wherein said gene delivery comprises a transfection of stem cells with a cDNA of at least one pancreatic gene under the control of a regulatory region allowing the initiation of transcription.
10. The method of claim 8, wherein said gene delivery comprises a DNA transfer using a viral delivery system.
11. The method of any one of claims 1-7, wherein the gene activation comprises a delivery of a protein product of a pancreatic gene into stem cells.
12. The method of any one of claims 2-11, wherein said embryoid bodies are formed by a hanging drop method.
13. The method of any one of claims 2-12, wherein said differentiation medium is based on Iscove's modified Dulbecco's medium (IMDM) supplemented with fetal calf serum, L-glutamine, non-essential amino acids, and α -monothioglycerol optionally containing EGF, bFGF, progesterone, growth hormone, follistatin, and/or activin.
14. The method of claim 13, wherein said differentiation medium further contains extracellular matrix proteins, collagens, and/or mixtures of growth factors and extracellular matrix proteins.
15. The method of any one of claims 1-14, wherein at least 20% insulin-producing cells are obtained after a differentiation time of 15 days.

16. The method of claim 15, wherein at least 40% insulin-producing cells are obtained.

5 17. The method of any one of claims 1-16 further comprising a selection of nestin-positive cells.

18. The method of any one of claims 1-17, wherein the insulin-producing cells are used for pharmaceutical applications.

10 19. The method of claim 18 for the treatment of pancreatic diseases, metabolic syndrome and metabolic disorders with impaired glucose levels, such as diabetes, hyperglycaemia, and/or impaired glucose tolerance.

15 20. The method of claim 18 or 19, wherein between 3000 and 100000 equivalent differentiated insulin-producing cells are administered per kilogram body weight.

20 21. A cell composition comprising insulin-producing cells obtainable by the method of any one of claims 1-17.

22. The composition of claim 21 comprising at least 20% insulin-producing cells after a differentiation time of 15 days.

25 23. The composition of claim 22 comprising at least 40% insulin-producing cells.

30 24. The composition of any one of claims 21-23 comprising a ratio of insulin-producing cells versus glucagon-producing cells of at least 2:1.

25. The composition of claim 24 comprising a ratio of at least 5:1.

- 32 -

26. The composition of any one of claims 21-25 exhibiting an increase in the insulin secretion of at least 2-fold 15 min after stimulation with 27.7 mM glucose.
- 5 27. The composition of any one of claims 21-26, which is a pharmaceutical composition.
28. The composition of claim 27 for the treatment of pancreatic diseases, metabolic syndrome and metabolic disorders with impaired glucose levels, such as diabetes, hyperglycaemia, and/or impaired glucose tolerance.
- 10 29. The composition of claim 27 or 28, which is administered by transplantation or used in a medical device.
- 15 30. A method for identifying and/or characterizing compounds capable of modulating the differentiation of stems cells into insulin-producing cells comprising:
contacting a compound to be tested with stem cells under
20 conditions wherein the stem cells are capable of being differentiated into insulin-producing cells and determining the effect of the compound on the differentiation process.
- 25 31. The method of claim 30 comprising transfecting stem cells with a DNA construct containing a reporter gene under regulatory control of a gene involved in β -cell differentiation, contacting said transfected cells with a compound to be tested and determining the activity of the reporter gene.
- 30 32. The method of claim 30 or 31 comprising contacting embryoid bodies which are cultivated in a differentiation medium enhancing β -

- 33 -

cell differentiation with a compound to be tested and determining differentiation into insulin-producing cells.




Figure 1

2/11




Figure 2

3/11




Figure 3

4/11

Analysis of mRNA level of genes involved in pancreatic β cell development in differentiating wt, Pdx-1⁺, and Pax4⁺ ES cells




Figure 4

5/11




Figure 5

6/11

Insulin-producing cells vs. glucagon-producing cells




Figure 6

7/11

Pax4 ES-cell derived insulin cells respond to glucose




Figure 7

8/11




Figure 8

Figure 9


Drug screening strategy

High throughput screening



Pax Promotor Reporter gene



- AR42J
- CAPAN-1
- mouse ES



Cell line

Medium throughput validation

10/11




Figure 10

11/11




Figure 11

SEQUENCE LISTING

<110> DeveloGen A.G.

<120> A Method For Differentiating Stem Cells Into
Insulin-Producing Cells

<130> Insulin-ES cells

<140>

<141>

<160> 20

<170> PatentIn Ver. 2.1

<210> 1

<211> 1122

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (54)..(905)

<400> 1

```

cctggcttgt agctcggacc cggggctgct ggccccaagt gccgggtgcc acc atg      56
                                     Met
                                     1

aac agt gag gag cag tac tac gcg gcc aca cag ctc tac aag gac ccg      104
Asn Ser Glu Glu Gln Tyr Tyr Ala Ala Thr Gln Leu Tyr Lys Asp Pro
                    5                      10                      15

tgc gca ttc cag agg ggc ccg gtg cca gag ttc agc gct aac ccc cct      152
Cys Ala Phe Gln Arg Gly Pro Val Pro Glu Phe Ser Ala Asn Pro Pro
                    20                      25                      30

gcg tgc ctg tac atg ggc cgc cag ccc cca cct ccg ccg cca ccc cag      200
Ala Cys Leu Tyr Met Gly Arg Gln Pro Pro Pro Pro Pro Pro Gln
                    35                      40                      45

ttt aca agc tcg ctg gga tca ctg gag cag gga agt cct ccg gac atc      248
Phe Thr Ser Ser Leu Gly Ser Leu Glu Gln Gly Ser Pro Pro Asp Ile
                    50                      55                      60                      65

tcc cca tac gaa gtg ccc ccg ctc gcc tcc gac gac ccg gct ggc gct      296
Ser Pro Tyr Glu Val Pro Pro Leu Ala Ser Asp Asp Pro Ala Gly Ala

```

70										75										80									
cac	ctc	cac	cac	cac	ctt	cca	gct	cag	ctc	ggg	ctc	gcc	cat	cca	cct					344									
His	Leu	His	His	His	Leu	Pro	Ala	Gln	Leu	Gly	Leu	Ala	His	Pro	Pro														
				85						90					95														
ccc	gga	cct	ttc	cgg	aat	gga	acc	gag	cct	ggg	ggc	ctg	gaa	gag	ccc					392									
Pro	Gly	Pro	Phe	Pro	Asn	Gly	Thr	Glu	Pro	Gly	Gly	Leu	Glu	Glu	Pro														
		100						105					110																
aac	cgc	gtc	cag	ctc	cct	ttc	cgg	tgg	atg	aaa	tcc	acc	aaa	gct	cac					440									
Asn	Arg	Val	Gln	Leu	Pro	Phe	Pro	Trp	Met	Lys	Ser	Thr	Lys	Ala	His														
		115				120						125																	
gcg	tgg	aaa	ggc	cag	tgg	gca	gga	ggt	gct	tac	aca	gcg	gaa	ccc	gag					488									
Ala	Trp	Lys	Gly	Gln	Trp	Ala	Gly	Gly	Ala	Tyr	Thr	Ala	Glu	Pro	Glu														
		130				135				140				145															
gaa	aac	aag	agg	acc	cgt	act	gcc	tac	acc	cgg	gcg	cag	ctg	ctg	gag					536									
Glu	Asn	Lys	Arg	Thr	Arg	Thr	Ala	Tyr	Thr	Arg	Ala	Gln	Leu	Leu	Glu														
				150					155					160															
ctg	gag	aag	gaa	ttc	tta	ttt	aac	aaa	tac	atc	tcc	cgg	ccc	cgc	cgg					584									
Leu	Glu	Lys	Glu	Phe	Leu	Phe	Asn	Lys	Tyr	Ile	Ser	Arg	Pro	Arg	Arg														
			165				170						175																
gtg	gag	ctg	gca	gtg	atg	ttg	aac	ttg	acc	gag	aga	cac	atc	aaa	atc					632									
Val	Glu	Leu	Ala	Val	Met	Leu	Asn	Leu	Thr	Glu	Arg	His	Ile	Lys	Ile														
		180				185						190																	
tgg	ttc	caa	aac	cgt	cgc	atg	aag	tgg	aaa	aaa	gag	gaa	gat	aag	aaa					680									
Trp	Phe	Gln	Asn	Arg	Arg	Met	Lys	Trp	Lys	Lys	Glu	Ala	Asp	Lys	Lys														
		195				200						205																	
cgt	agt	agc	ggg	acc	ccg	agt	ggg	ggc	ggt	ggg	ggc	gaa	gag	ccg	gag					728									
Arg	Ser	Ser	Gly	Thr	Pro	Ser	Gly	Gly	Gly	Gly	Gly	Glu	Glu	Pro	Glu														
		210			215				220					225															
caa	gat	tgt	gcg	gtg	acc	tcg	ggc	gag	gag	ctg	ctg	gca	gtg	cca	ccg					776									
Gln	Asp	Cys	Ala	Val	Thr	Ser	Gly	Glu	Glu	Leu	Leu	Ala	Val	Pro	Pro														
			230					235					240																
ctg	cca	cct	ccc	gga	ggt	gcc	gtg	ccc	cca	ggc	gtc	cca	gct	gca	gtc					824									
Leu	Pro	Pro	Pro	Gly	Gly	Ala	Val	Pro	Pro	Gly	Val	Pro	Ala	Ala	Val														
			245			250							255																
cgg	gag	ggc	cta	ctg	cct	tcg	ggc	ctt	agc	gtg	tcg	cca	cag	ccc	tcc					872									
Arg	Glu	Gly	Leu	Leu	Pro	Ser	Gly	Leu	Ser	Val	Ser	Pro	Gln	Pro	Ser														

260

265

270

agc atc gcg cca ctg cga ccg cag gaa ccc cgg tgaggacagc agtctgaggg 925
 Ser Ile Ala Pro Leu Arg Pro Gln Glu Pro Arg

275

280

tgagcgggtc tgggaccocag agtgtggacg tgggagcggg cagctggata agggaaactta 985

acctaggcgt cgcacaagaa gaaaattctt gagggcacga gagccagttg gatagccgga 1045

gagatgtgc gagcttctgg aaaaacagcc ctgagcttct gaaaactttg aggtgcttc 1105

tgatgccaag ctaatgg

1122

<210> 2

<211> 284

<212> PRT

<213> Mus musculus

<400> 2

Met Asn Ser Glu Glu Gln Tyr Tyr Ala Ala Thr Gln Leu Tyr Lys Asp

1

5

10

15

Pro Cys Ala Phe Gln Arg Gly Pro Val Pro Glu Phe Ser Ala Asn Pro

20

25

30

Pro Ala Cys Leu Tyr Met Gly Arg Gln Pro Pro Pro Pro Pro Pro Pro

35

40

45

Gln Phe Thr Ser Ser Leu Gly Ser Leu Glu Gln Gly Ser Pro Pro Asp

50

55

60

Ile Ser Pro Tyr Glu Val Pro Pro Leu Ala Ser Asp Asp Pro Ala Gly

65

70

75

80

Ala His Leu His His His Leu Pro Ala Gln Leu Gly Leu Ala His Pro

85

90

95

Pro Pro Gly Pro Phe Pro Asn Gly Thr Glu Pro Gly Gly Leu Glu Glu

100

105

110

Pro Asn Arg Val Gln Leu Pro Phe Pro Trp Met Lys Ser Thr Lys Ala

115

120

125

His Ala Trp Lys Gly Gln Trp Ala Gly Gly Ala Tyr Thr Ala Glu Pro

130

135

140

Glu Glu Asn Lys Arg Thr Arg Thr Ala Tyr Thr Arg Ala Gln Leu Leu
145 150 155 160

Glu Leu Glu Lys Glu Phe Leu Phe Asn Lys Tyr Ile Ser Arg Pro Arg
165 170 175

Arg Val Glu Leu Ala Val Met Leu Asn Leu Thr Glu Arg His Ile Lys
180 185 190

Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys Glu Glu Asp Lys
195 200 205

Lys Arg Ser Ser Gly Thr Pro Ser Gly Gly Gly Gly Gly Glu Glu Pro
210 215 220

Glu Gln Asp Cys Ala Val Thr Ser Gly Glu Glu Leu Leu Ala Val Pro
225 230 235 240

Pro Leu Pro Pro Pro Gly Gly Ala Val Pro Pro Gly Val Pro Ala Ala
245 250 255

Val Arg Glu Gly Leu Leu Pro Ser Gly Leu Ser Val Ser Pro Gln Pro
260 265 270

Ser Ser Ile Ala Pro Leu Arg Pro Gln Glu Pro Arg
275 280

<210> 3

<211> 1084

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (24)..(1019)

<400> 3

tcgcgaggagt accagtgatga agc atg cag cag gac gga ctc agc agt gtg aat 53

Met Gln Gln Asp Gly Leu Ser Ser Val Asn

1

5

10

cag cta ggg gga ctc ttt gtg aat ggc cgg ccc ctt cct ctg gac acc 101

Gln Leu Gly Gly Leu Phe Val Asn Gly Arg Pro Leu Pro Leu Asp Thr

15

20

25

agg cag cag att gtg cag cta gca ata aga ggg atg cga ccc tgt gac 149

Arg	Gln	Gln	Ile	Val	Gln	Leu	Ala	Ile	Arg	Gly	Met	Arg	Pro	Cys	Asp	
			30					35					40			
att	tca	egg	agc	ctt	aag	gta	tct	aat	ggc	tgt	gtg	agc	aag	atc	cta	197
Ile	Ser	Arg	Ser	Leu	Lys	Val	Ser	Asn	Gly	Cys	Val	Ser	Lys	Ile	Leu	
		45					50					55				
gga	cgc	tac	tac	cgc	aca	ggg	gtc	ttg	gaa	ccc	aag	tgt	att	ggg	gga	245
Gly	Arg	Tyr	Tyr	Arg	Thr	Gly	Val	Leu	Glu	Pro	Lys	Cys	Ile	Gly	Gly	
		60				65					70					
agc	aaa	cca	cgt	ctg	gcc	aca	cct	gct	gtg	gtg	gct	cga	att	gcc	cag	293
Ser	Lys	Pro	Arg	Leu	Ala	Thr	Pro	Ala	Val	Val	Ala	Arg	Ile	Ala	Gln	
		75				80				85				90		
cta	aag	gat	gag	tac	cct	gct	ctt	ttt	gcc	tgg	gag	atc	caa	cac	cag	341
Leu	Lys	Asp	Glu	Tyr	Pro	Ala	Leu	Phe	Ala	Trp	Glu	Ile	Gln	His	Gln	
				95					100					105		
ctt	tgc	act	gaa	ggg	ctt	tgt	acc	cag	gac	aag	gct	ccc	agt	gtg	tcc	389
Leu	Cys	Thr	Glu	Gly	Leu	Cys	Thr	Gln	Asp	Lys	Ala	Pro	Ser	Val	Ser	
			110				115						120			
tct	atc	aat	cga	gta	ctt	egg	gca	ctt	cag	gaa	gac	cag	agc	ttg	cac	437
Ser	Ile	Asn	Arg	Val	Leu	Arg	Ala	Leu	Gln	Glu	Asp	Gln	Ser	Leu	His	
		125					130					135				
tgg	act	caa	ctc	aga	tca	cca	gct	gtg	ttg	gct	cca	gtt	ctt	ccc	agt	485
Trp	Thr	Gln	Leu	Arg	Ser	Pro	Ala	Val	Leu	Ala	Pro	Val	Leu	Pro	Ser	
		140				145					150					
ccc	cac	agt	aac	tgt	ggg	gct	ccc	cga	ggc	ccc	cac	cca	gga	acc	agc	533
Pro	His	Ser	Asn	Cys	Gly	Ala	Pro	Arg	Gly	Pro	His	Pro	Gly	Thr	Ser	
		155			160					165				170		
cac	agg	aat	egg	gct	atc	ttc	tcc	ccg	gga	caa	gcc	gag	gca	ctg	gag	581
His	Arg	Asn	Arg	Ala	Ile	Phe	Ser	Pro	Gly	Gln	Ala	Glu	Ala	Leu	Glu	
			175					180					185			
aaa	gag	ttt	cag	cgt	ggg	cag	tat	cca	gat	tca	gtg	gcc	cgt	ggg	aag	629
Lys	Glu	Phe	Gln	Arg	Gly	Gln	Tyr	Pro	Asp	Ser	Val	Ala	Arg	Gly	Lys	
		190						195					200			
ctg	gct	gct	gcc	acc	tct	ctg	cct	gaa	gac	acg	gtg	agg	gtt	tgg	ttt	677
Leu	Ala	Ala	Ala	Thr	Ser	Leu	Pro	Glu	Asp	Thr	Val	Arg	Val	Trp	Phe	
		205					210						215			
tct	aac	aga	aga	gcc	aaa	tgg	cgc	agg	caa	gag	aag	ctg	aaa	tgg	gaa	725

Ser Asn Arg Arg Ala Lys Trp Arg Arg Gln Glu Lys Leu Lys Trp Glu
 220 225 230
 gca cag ctg cca ggt gct tcc cag gac ctg acg ata cca aaa aat tct 773
 Ala Gln Leu Pro Gly Ala Ser Gln Asp Leu Thr Ile Pro Lys Asn Ser
 235 240 245 250
 cca ggg atc atc tct gca cag cag tcc ccc ggc agt gta ccc tca gct 821
 Pro Gly Ile Ile Ser Ala Gln Gln Ser Pro Gly Ser Val Pro Ser Ala
 255 260 265
 gcc ttg cct gtg ctg gaa cca ttg agt cct tcc ttc tgt cag cta tgc 869
 Ala Leu Pro Val Leu Glu Pro Leu Ser Pro Ser Phe Cys Gln Leu Cys
 270 275 280
 tgt ggg aca gca cca ggc aga tgt tcc agt gac acc tca tcc cag gcc 917
 Cys Gly Thr Ala Pro Gly Arg Cys Ser Ser Asp Thr Ser Ser Gln Ala
 285 290 295
 tat ctc caa ccc tac tgg gac tgc caa tcc ctc ctt cct gtg gct tcc 965
 Tyr Leu Gln Pro Tyr Trp Asp Cys Gln Ser Leu Leu Pro Val Ala Ser
 300 305 310
 tcc tca tat gtg gaa ttt gcc tgc cct gcc tca cca ccc atc ctg tgc 1013
 Ser Ser Tyr Val Glu Phe Ala Cys Pro Ala Ser Pro Pro Ile Leu Cys
 315 320 325 330
 atc atc tgattggagg cccaggacaa gtgccatcat cccattgctc aaactggcca 1069
 Ile Ile
 taaccgcgga attcc 1084

<210> 4

<211> 332

<212> PRT

<213> Mus musculus

<400> 4

Met Gln Gln Asp Gly Leu Ser Ser Val Asn Gln Leu Gly Gly Leu Phe
 1 5 10 15
 Val Asn Gly Arg Pro Leu Pro Leu Asp Thr Arg Gln Gln Ile Val Gln
 20 25 30
 Leu Ala Ile Arg Gly Met Arg Pro Cys Asp Ile Ser Arg Ser Leu Lys
 35 40 45

Val Ser Asn Gly Cys Val Ser Lys Ile Leu Gly Arg Tyr Tyr Arg Thr
 50 55 60

Gly Val Leu Glu Pro Lys Cys Ile Gly Gly Ser Lys Pro Arg Leu Ala
 65 70 75 80

Thr Pro Ala Val Val Ala Arg Ile Ala Gln Leu Lys Asp Glu Tyr Pro
 85 90 95

Ala Leu Phe Ala Trp Glu Ile Gln His Gln Leu Cys Thr Glu Gly Leu
 100 105 110

Cys Thr Gln Asp Lys Ala Pro Ser Val Ser Ser Ile Asn Arg Val Leu
 115 120 125

Arg Ala Leu Gln Glu Asp Gln Ser Leu His Trp Thr Gln Leu Arg Ser
 130 135 140

Pro Ala Val Leu Ala Pro Val Leu Pro Ser Pro His Ser Asn Cys Gly
 145 150 155 160

Ala Pro Arg Gly Pro His Pro Gly Thr Ser His Arg Asn Arg Ala Ile
 165 170 175

Phe Ser Pro Gly Gln Ala Glu Ala Leu Glu Lys Glu Phe Gln Arg Gly
 180 185 190

Gln Tyr Pro Asp Ser Val Ala Arg Gly Lys Leu Ala Ala Ala Thr Ser
 195 200 205

Leu Pro Glu Asp Thr Val Arg Val Trp Phe Ser Asn Arg Arg Ala Lys
 210 215 220

Trp Arg Arg Gln Glu Lys Leu Lys Trp Glu Ala Gln Leu Pro Gly Ala
 225 230 235 240

Ser Gln Asp Leu Thr Ile Pro Lys Asn Ser Pro Gly Ile Ile Ser Ala
 245 250 255

Gln Gln Ser Pro Gly Ser Val Pro Ser Ala Ala Leu Pro Val Leu Glu
 260 265 270

Pro Leu Ser Pro Ser Phe Cys Gln Leu Cys Cys Gly Thr Ala Pro Gly
 275 280 285

Arg Cys Ser Ser Asp Thr Ser Ser Gln Ala Tyr Leu Gln Pro Tyr Trp
 290 295 300

Asp Cys Gln Ser Leu Leu Pro Val Ala Ser Ser Ser Tyr Val Glu Phe
 305 310 315 320

Ala Cys Pro Ala Ser Pro Pro Ile Leu Cys Ile Ile
 325 330

<210> 5

<211> 1872

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (30)..(1337)

<400> 5

ggatccggag gctgccaacc agctccagc atg cag aac agt cac agc gga gtg 53
 Met Gln Asn Ser His Ser Gly Val
 1 5

aat cag ctt ggt ggt gtc ttt gtc aac ggg cgg cca ctg ccg gac tcc 101
 Asn Gln Leu Gly Gly Val Phe Val Asn Gly Arg Pro Leu Pro Asp Ser
 10 15 20

acc cgg cag aag atc gta gag cta gct cac agc ggg gcc cgg ccg tgc 149
 Thr Arg Gln Lys Ile Val Glu Leu Ala His Ser Gly Ala Arg Pro Cys
 25 30 35 40

gac att tcc cga att ctg cag acc cat gca gat gca aaa gtc cag gtg 197
 Asp Ile Ser Arg Ile Leu Gln Thr His Ala Asp Ala Lys Val Gln Val
 45 50 55

ctg gac aat gaa aac gta tcc aac ggt tgt gtg agt aaa att ctg ggc 245
 Leu Asp Asn Glu Asn Val Ser Asn Gly Cys Val Ser Lys Ile Leu Gly
 60 65 70

agg tat tac gag act ggc tcc atc aga ccc agg gca atc gga ggg agt 293
 Arg Tyr Tyr Glu Thr Gly Ser Ile Arg Pro Arg Ala Ile Gly Gly Ser
 75 80 85

aag cca aga gtg gcg act cca gaa gtt gta agc aaa ata gcc cag tat 341
 Lys Pro Arg Val Ala Thr Pro Glu Val Val Ser Lys Ile Ala Gln Tyr
 90 95 100

aaa cgg gag tgc cct tcc atc ttt gct tgg gaa atc cga gac aga tta 389
 Lys Arg Glu Cys Pro Ser Ile Phe Ala Trp Glu Ile Arg Asp Arg Leu

105	110	115	120	
tta tcc gag ggg gtc tgt acc aac gat aac ata ccc agt gtg tca tca				437
Leu Ser Glu Gly Val Cys Thr Asn Asp Asn Ile Pro Ser Val Ser Ser				
	125	130	135	
ata aac aga gtt ctt cgc aac ctg gct agc gaa aag caa cag atg ggc				485
Ile Asn Arg Val Leu Arg Asn Leu Ala Ser Glu Lys Gln Gln Met Gly				
	140	145	150	
gca gac ggc atg tat gat aaa cta agg atg ttg aac ggg cag acc gga				533
Ala Asp Gly Met Tyr Asp Lys Leu Arg Met Leu Asn Gly Gln Thr Gly				
	155	160	165	
agc tgg ggc aca cgc cct ggt tgg tat ccc ggg act tca gta cca ggg				581
Ser Trp Gly Thr Arg Pro Gly Trp Tyr Pro Gly Thr Ser Val Pro Gly				
	170	175	180	
caa ccc acg caa gat ggc tgc cag caa cag gaa gga ggg gga gag aac				629
Gln Pro Thr Gln Asp Gly Cys Gln Gln Gln Glu Gly Gly Gly Glu Asn				
	185	190	200	
acc aac tcc atc agt tct aac gga gaa gac tcc gat gaa gct cag atg				677
Thr Asn Ser Ile Ser Ser Asn Gly Glu Asp Ser Asp Glu Ala Gln Met				
	205	210	215	
cga ctt cag ctg aag cgg aag ctg caa aga aat aga aca tct ttt acc				725
Arg Leu Gln Leu Lys Arg Lys Leu Gln Arg Asn Arg Thr Ser Phe Thr				
	220	225	230	
caa gag cag att gag gct ctg gag aaa gag ttt gag agg acc cat tat				773
Gln Glu Gln Ile Glu Ala Leu Glu Lys Glu Phe Glu Arg Thr His Tyr				
	235	240	245	
cca gat gtg ttt gcc cgg gaa aga cta gca gcc aaa ata gat cta cct				821
Pro Asp Val Phe Ala Arg Glu Arg Leu Ala Ala Lys Ile Asp Leu Pro				
	250	255	260	
gaa gca aga ata cag gta tgg ttt tct aat cga agg gcc aaa tgg aga				869
Glu Ala Arg Ile Gln Val Trp Phe Ser Asn Arg Arg Ala Lys Trp Arg				
	265	270	275	280
aga gaa gag aaa ctg agg aac cag aga aga cag gcc agc aac act cct				917
Arg Glu Glu Lys Leu Arg Asn Gln Arg Gln Ala Ser Asn Thr Pro				
	285	290	295	
agt cac att cct atc agc agc agc ttc agt acc agt gtc tac cag cca				965
Ser His Ile Pro Ile Ser Ser Ser Phe Ser Thr Ser Val Tyr Gln Pro				

300	305	310	
atc cca cag gcc acc aca cct gtc tcc tcc ttc aca tca ggt tcc atg			1013
Ile Pro Gln Pro Thr Thr Pro Val Ser Ser Phe Thr Ser Gly Ser Met			
315	320	325	
ttg ggc cga aca gac acc gcc ctc acc aac acg tac agt gct ttg cca			1061
Leu Gly Arg Thr Asp Thr Ala Leu Thr Asn Thr Tyr Ser Ala Leu Pro			
330	335	340	
ccc atg ccc agc ttc acc atg gca aac aac ctg cct atg caa ccc cca			1109
Pro Met Pro Ser Phe Thr Met Ala Asn Asn Leu Pro Met Gln Pro Pro			
345	350	355	360
gtc ccc agt cag acc tcc tca tac tcg tgc atg ctg ccc acc agc ccg			1157
Val Pro Ser Gln Thr Ser Ser Tyr Ser Cys Met Leu Pro Thr Ser Pro			
365	370	375	
tca gtg aat ggg cgg agt tat gat acc tac acc cct cgg cac atg caa			1205
Ser Val Asn Gly Arg Ser Tyr Asp Thr Tyr Thr Pro Pro His Met Gln			
380	385	390	
aca cac atg aac agt cag ccc atg ggc acc tcg ggg acc act tca aca			1253
Thr His Met Asn Ser Gln Pro Met Gly Thr Ser Gly Thr Thr Ser Thr			
395	400	405	
gga ctc att tca cct gga gtg tca gtt ccc gtc caa gtt ccc ggg agt			1301
Gly Leu Ile Ser Pro Gly Val Ser Val Pro Val Gln Val Pro Gly Ser			
410	415	420	
gaa cct gac atg tct cag tac tgg cct cga tta cag taaagagaga			1347
Glu Pro Asp Met Ser Gln Tyr Trp Pro Arg Leu Gln			
425	430	435	
aggagagagc atgtgatcga gagaggaaat tgtgttcact ctgccaatga ctatgtggac			1407
acagcagttg ggtattcagg aaagaaagag aaatggcggt tagaagcact tcactttgta			1467
actgtcctga actggagccc gggaatggac tagaaccaag gacctgtcgt acagaaggca			1527
cggtatcagt tggaacaaat cttcattttg gtatccaaac ttttattcat tttggtgtat			1587
tattttgtaaa tgggcatttg tatgttataa tgaagaaaag aacaacacag gctgttggat			1647
cgcggtatctg tgttgtcat gtggtgtttt aaaggaaacc atgatcgaca agatttgcca			1707
tggatttaag agttttatca agatatatca aatacttctc cccatctgtt catagtttat			1767

ggactgatgt tccaagtttg tatcattctt ttgcataaa ttgaacctgg gacaacacac 1827

actagatata tgtaaaaact atctgttggt ttccaaaagg ttggt 1872

<210> 6

<211> 436

<212> PRT

<213> Mus musculus

<400> 6

Met Gln Asn Ser His Ser Gly Val Asn Gln Leu Gly Gly Val Phe Val
1 5 10 15

Asn Gly Arg Pro Leu Pro Asp Ser Thr Arg Gln Lys Ile Val Glu Leu
20 25 30

Ala His Ser Gly Ala Arg Pro Cys Asp Ile Ser Arg Ile Leu Gln Thr
35 40 45

His Ala Asp Ala Lys Val Gln Val Leu Asp Asn Glu Asn Val Ser Asn
50 55 60

Gly Cys Val Ser Lys Ile Leu Gly Arg Tyr Tyr Glu Thr Gly Ser Ile
65 70 75 80

Arg Pro Arg Ala Ile Gly Gly Ser Lys Pro Arg Val Ala Thr Pro Glu
85 90 95

Val Val Ser Lys Ile Ala Gln Tyr Lys Arg Glu Cys Pro Ser Ile Phe
100 105 110

Ala Trp Glu Ile Arg Asp Arg Leu Leu Ser Glu Gly Val Cys Thr Asn
115 120 125

Asp Asn Ile Pro Ser Val Ser Ser Ile Asn Arg Val Leu Arg Asn Leu
130 135 140

Ala Ser Glu Lys Gln Gln Met Gly Ala Asp Gly Met Tyr Asp Lys Leu
145 150 155 160

Arg Met Leu Asn Gly Gln Thr Gly Ser Trp Gly Thr Arg Pro Gly Trp
165 170 175

Tyr Pro Gly Thr Ser Val Pro Gly Gln Pro Thr Gln Asp Gly Cys Gln
180 185 190

Gln Gln Glu Gly Gly Gly Glu Asn Thr Asn Ser Ile Ser Ser Asn Gly

195	200	205
Glu Asp Ser Asp Glu Ala Gln Met Arg Leu Gln Leu Lys Arg Lys Leu 210	215	220
Gln Arg Asn Arg Thr Ser Phe Thr Gln Glu Gln Ile Glu Ala Leu Glu 225	230	235 240
Lys Glu Phe Glu Arg Thr His Tyr Pro Asp Val Phe Ala Arg Glu Arg 245	250	255
Leu Ala Ala Lys Ile Asp Leu Pro Glu Ala Arg Ile Gln Val Trp Phe 260	265	270
Ser Asn Arg Arg Ala Lys Trp Arg Arg Glu Glu Lys Leu Arg Asn Gln 275	280	285
Arg Arg Gln Ala Ser Asn Thr Pro Ser His Ile Pro Ile Ser Ser Ser 290	295	300
Phe Ser Thr Ser Val Tyr Gln Pro Ile Pro Gln Pro Thr Thr Pro Val 305	310	315 320
Ser Ser Phe Thr Ser Gly Ser Met Leu Gly Arg Thr Asp Thr Ala Leu 325	330	335
Thr Asn Thr Tyr Ser Ala Leu Pro Pro Met Pro Ser Phe Thr Met Ala 340	345	350
Asn Asn Leu Pro Met Gln Pro Pro Val Pro Ser Gln Thr Ser Ser Tyr 355	360	365
Ser Cys Met Leu Pro Thr Ser Pro Ser Val Asn Gly Arg Ser Tyr Asp 370	375	380
Thr Tyr Thr Pro Pro His Met Gln Thr His Met Asn Ser Gln Pro Met 385	390	395 400
Gly Thr Ser Gly Thr Thr Ser Thr Gly Leu Ile Ser Pro Gly Val Ser 405	410	415
Val Pro Val Gln Val Pro Gly Ser Glu Pro Asp Met Ser Gln Tyr Trp 420	425	430
Pro Arg Leu Gln 435		

<210> 7

<211> 861

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (160)..(801)

<400> 7

```

attcttttga gtcgggagaa ctaggtaaca attcggaaac tccaaagggt ggatgagggg 60
cgcgcggggt gtgtgtgggg gatactctgg tccccctgac agtgacctct aagtcagagg 120
ctggcacaca cacaccttcc attttttccc aaccgcagg atg gcg cct cat ccc 174
                                     Met Ala Pro His Pro
                                     1 5
ttg gat gcg ctc acc atc caa gtg tcc cca gag aca caa caa cct ttt 222
Leu Asp Ala Leu Thr Ile Gln Val Ser Pro Glu Thr Gln Gln Pro Phe
                                     10 15 20
ccc gga gcc tcg gac cac gaa gtg ctc agt tcc aat tcc acc cca cct 270
Pro Gly Ala Ser Asp His Glu Val Leu Ser Ser Asn Ser Thr Pro Pro
                                     25 30 35
agc ccc act ctc ata cct agg gac tgc tcc gaa gca gaa gtg ggt gac 318
Ser Pro Thr Leu Ile Pro Arg Asp Cys Ser Glu Ala Glu Val Gly Asp
                                     40 45 50
tgc cga ggg acc tcg agg aag ctc cgc gcc cga cgc gga ggg cgc aac 366
Cys Arg Gly Thr Ser Arg Lys Leu Arg Ala Arg Arg Gly Gly Arg Asn
                                     55 60 65
agg ccc aag agc gag ttg gca ctc agc aaa cag cga aga agc cgg cgc 414
Arg Pro Lys Ser Glu Leu Ala Leu Ser Lys Gln Arg Arg Ser Arg Arg
                                     70 75 80 85
aag aag gcc aat gat cgg gag cgc aat cgc atg cac aac ctc aac tcg 462
Lys Lys Ala Asn Asp Arg Glu Arg Asn Arg Met His Asn Leu Asn Ser
                                     90 95 100
gcg ctg gat gcg ctg cgc ggt gtc ctg ccc acc ttc ccg gat gac gcc 510
Ala Leu Asp Ala Leu Arg Gly Val Leu Pro Thr Phe Pro Asp Asp Ala
                                     105 110 115
aaa ctt aca aag atc gag acc ctg cgc ttc gcc cac aac tac atc tgg 558

```

Lys Leu Thr Lys Ile Glu Thr Leu Arg Phe Ala His Asn Tyr Ile Trp
 120 125 130
 gca ctg act cag acg ctg cgc ata gcg gac cac agc ttc tat ggc ccg 606
 Ala Leu Thr Gln Thr Leu Arg Ile Ala Asp His Ser Phe Tyr Gly Pro
 135 140 145
 gag ccc cct gtg ccc tgt gga gag ctg ggg agc ccc gga ggt ggc tcc 654
 Glu Pro Pro Val Pro Cys Gly Glu Leu Gly Ser Pro Gly Gly Gly Ser
 150 155 160 165
 aac ggg gac tgg ggc tct atc tac tcc cca gtc tcc caa gcg ggt aac 702
 Asn Gly Asp Trp Gly Ser Ile Tyr Ser Pro Val Ser Gln Ala Gly Asn
 170 175 180
 ctg agc ccc acg gcc tca ttg gag gaa ttc cct ggc ctg cag gtg ccc 750
 Leu Ser Pro Thr Ala Ser Leu Glu Glu Phe Pro Gly Leu Gln Val Pro
 185 190 195
 agc tcc cca tcc tat ctg ctc ccg gga gca ctg gtg ttc tca gac ttc 798
 Ser Ser Pro Ser Tyr Leu Leu Pro Gly Ala Leu Val Phe Ser Asp Phe
 200 205 210
 ttg tgaagagacc tgtctggctc tgggtggtgg gtgctagtgg aaagggaggg 851
 Leu
 gaccacagcc 861
 <210> 8
 <211> 214
 <212> PRT
 <213> Mus musculus
 <400> 8
 Met Ala Pro His Pro Leu Asp Ala Leu Thr Ile Gln Val Ser Pro Glu
 1 5 10 15
 Thr Gln Gln Pro Phe Pro Gly Ala Ser Asp His Glu Val Leu Ser Ser
 20 25 30
 Asn Ser Thr Pro Pro Ser Pro Thr Leu Ile Pro Arg Asp Cys Ser Glu
 35 40 45
 Ala Glu Val Gly Asp Cys Arg Gly Thr Ser Arg Lys Leu Arg Ala Arg
 50 55 60
 Arg Gly Gly Arg Asn Arg Pro Lys Ser Glu Leu Ala Leu Ser Lys Gln

65	70	75	80
Arg Arg Ser Arg Arg Lys Lys Ala Asn Asp Arg Glu Arg Asn Arg Met	85	90	95
His Asn Leu Asn Ser Ala Leu Asp Ala Leu Arg Gly Val Leu Pro Thr	100	105	110
Phe Pro Asp Asp Ala Lys Leu Thr Lys Ile Glu Thr Leu Arg Phe Ala	115	120	125
His Asn Tyr Ile Trp Ala Leu Thr Gln Thr Leu Arg Ile Ala Asp His	130	135	140
Ser Phe Tyr Gly Pro Glu Pro Pro Val Pro Cys Gly Glu Leu Gly Ser	145	150	155
Pro Gly Gly Gly Ser Asn Gly Asp Trp Gly Ser Ile Tyr Ser Pro Val	165	170	175
Ser Gln Ala Gly Asn Leu Ser Pro Thr Ala Ser Leu Glu Glu Phe Pro	180	185	190
Gly Leu Gln Val Pro Ser Ser Pro Ser Tyr Leu Leu Pro Gly Ala Leu	195	200	205
Val Phe Ser Asp Phe Leu	210		

<210> 9

<211> 21

<212> DNA

<213> Mus musculus

<400> 9

ttcggctatg acatcggtgt g

21

<210> 10

<211> 21

<212> DNA

<213> Mus musculus

<400> 10

agctgaggcc agcaatctga c

21

<210> 11
<211> 18
<212> DNA
<213> Mus musculus

<400> 11
cagcccttag tgaccaga 18

<210> 12
<211> 18
<212> DNA
<213> Mus musculus

<400> 12
atgctggtgc agcactga 18

<210> 13
<211> 18
<212> DNA
<213> Mus musculus

<400> 13
cgctgatcc cttggtg 18

<210> 14
<211> 18
<212> DNA
<213> Mus musculus

<400> 14
cagtcaccca cttctgct 18

<210> 15
<211> 20
<212> DNA
<213> Mus musculus

<400> 15
ctttccggtg gatgaaatcc 20

<210> 16
<211> 21

<212> DNA
<213> Mus musculus

<400> 16
gtcaagtcca acatcaactgc c

21

<210> 17
<211> 20
<212> DNA
<213> Mus musculus

<400> 17
gtttgtacgg gatcaaatgc

20

<210> 18
<211> 20
<212> DNA
<213> Mus musculus

<400> 18
atgctgcgtt tcttgcctt

20

<210> 19
<211> 20
<212> DNA
<213> Mus musculus

<400> 19
tcactgtgcc tgaacttacc

20

<210> 20
<211> 20
<212> DNA
<213> Mus musculus

<400> 20
ggaacatagc cgtaaactgc

20

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number
WO 02/086107 A3

- (51) International Patent Classification⁷: C12N 5/08, 5/02, A61K 35/39, 35/48, C12Q 1/02, A61P 5/48
- (21) International Application Number: PCT/EP02/04362
- (22) International Filing Date: 19 April 2002 (19.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/284,531 19 April 2001 (19.04.2001) US
- (71) Applicants (for all designated States except US):
DEVELOGEN AKTIENGESELLSCHAFT FÜR ENTWICKLUNGSBIOLOGISCHE FORSCHUNG [DE/DE]; Rudolf-Wissell-Strasse 28, 37079 Göttingen (DE). **INSTITUT FÜR PFLANZENGENETIK UND KULTURPFLANZENFORSCHUNG** [DE/DE]; Corrensstrasse 3, 06466 Gatersleben (DE).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **WOBUS, Anna, M.** [DE/DE]; Liebigweg 7, 06466 Gatersleben (DE). **ST-ONGE, Luc** [CA/DE]; Rautenbreite 5, 37077 Göttingen (DE). **BLYSZCZUK, Przemyslaw** [PL/DE]; Corrensstrasse 4a, 06466 Gatersleben (DE). **HOFFMANN, Ursula** [DE/DE]; Schedener Weg 28, 37127 Jühnde (DE).
- (74) Agents: **WEICKMANN, Franz, Albert et al.**; Weickmann & Weickmann, Postfach 86 08 20, 81635 München (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— with international search report
- (88) Date of publication of the international search report:
24 July 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A METHOD FOR DIFFERENTIATING STEM CELLS INTO INSULIN-PRODUCING CELLS

(57) Abstract: The present invention relates a novel method for differentiating stem cells into insulin-producing cells by culturing such cells in specially defined media and optimally, activating one or more genes involved in beta-cell differentiation. The present invention further relates to applications in the medical (particularly diabetes) field that directly arise from the method of the invention. Additionally, the present invention relates to applications for identifying and characterising compounds with therapeutic medical effects or toxicological effects that directly arise from the method of the invention.

WO 02/086107 A3

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 02/04362

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N5/08 C12N5/02 A61K35/39 A61K35/48 C12Q1/02
A61P5/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SORIA B ET AL: "Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice" DIABETES, vol. 49, no. 2, February 2000 (2000-02), pages 157-162, XP002183378 ISSN: 0012-1797 cited in the application the whole document</p> <p>---</p> <p>-/--</p>	1-32



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

27 March 2003

Date of mailing of the international search report

09/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Teyssier, B

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 02/04362

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	LUMELSKY N ET AL: "Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets" SCIENCE, vol. 292, no. 5520, 18 May 2001 (2001-05-18), pages 1389-1394, XP002183377 ISSN: 0036-8075 cited in the application the whole document	1-32
E	WO 02 059278 A (KIM JONG-HOON ;BLONDEL OLIVER (US); MC KAY RONALD D (US); GOVERNAME) 1 August 2002 (2002-08-01) examples	1-32
X,P	ASSADY S ET AL: "Insulin production by human embryonic stem cells." DIABETES, vol. 50, no. 8, August 2001 (2001-08), pages 1691-1697, XP002233758 ISSN: 0012-1797 cited in the application the whole document	1-32
X	ST-ONGE L ET AL: "Pancreas development and diabetes." CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 9, no. 3, June 1999 (1999-06), pages 295-300, XP002233759 ISSN: 0959-437X cited in the application table 1	1-32
X	GRAPIN-BOTTON A ET AL: "Key events of pancreas formation are triggered in gut endoderm by ectopic expression of pancreatic regulatory genes." GENES & DEVELOPMENT, vol. 15, no. 4, 15 February 2001 (2001-02-15), pages 444-454, XP002233760 ISSN: 0890-9369 the whole document	1-32
X,P	SORIA B: "In-vitro differentiation of pancreatic beta-cells." DIFFERENTIATION, vol. 68, no. 4-5, October 2001 (2001-10), pages 205-219, XP002233761 ISSN: 0301-4681 the whole document	1-32

-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 02/04362

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>BLYSZCZUK P ET AL: "Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 3, 4 February 2003 (2003-02-04), pages 998-1003, XP002233762 ISSN: 0027-8424</p> <p>-----</p>	

Information on patent family members

PCT/EP 02/04362

Patent document
cited in search report

Publication date

Patent family member(s)

Publication date

WO 02059278

A

01-08-2002

WO

02059278 A2.

01-08-2002